Can anything threaten Novo and Lilly's obesity market dominance? [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
There are two clear market leaders in the market for obesity drugs. Novo Nordisk and Eli Lilly are the only pharmaceutical companies with GLP-1 medications approved for weight loss, and the popularity of their drugs has made them household names. Since GLP-1s hit the market, the five biggest diabetes and obesity medications — Novo's Ozempic, Wegovy and Rybelsus, and Lilly's Zepbound and Mounjaro — have collectively raked in $71 billion in U.S. revenue since 2018, according to a recent report by the Initiative for Medicines, Access and Knowledge (I-MAK), a nonprofit focused on documenting what it sees as abuses in the patent system. Ozempic, which also has approvals in chronic kidney disease and heart disease, accounted for about half of that total. There's more growth to come. By 2030, cumulative revenue of those five GLP-1 drugs are projected to reach $470 billion, I-MAK estimated, which would make them some of the best-selling products of all time, according to Tahir Amin, CEO
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Lawsuits alleging GLP-1 drugs led to blindness to be centralized [Seeking Alpha]Seeking Alpha
- Update: Market Chatter: Eli Lilly Could Get FDA Decision for Weight-Loss Pill Orforglipron by March 2026 [Yahoo! Finance]Yahoo! Finance
- 2 Predictions for Novo Nordisk in 2026 [Yahoo! Finance]Yahoo! Finance
- Eli Lilly: The Right Long-Term Strategy [Seeking Alpha]Seeking Alpha
- Novo Nordisk A/S: More efficacious dose of Wegovy® recommended by the European Medicines Agency can help people with obesity achieve an average of 20.7% weight loss [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website